Nevro Corp share price today

(NVRO)

Nevro Corp share price is $4.35 & ₹368.37 as on 10 Dec 2024, 2.30 'hrs' IST

$4.35

▲

0.16

(3.82%)

Market is closed - opens 8 PM, 10 Dec 2024

View live Nevro Corp share price in Dollar and Rupees. Guide to invest in Nevro Corp from India. Also see the sentimental analysis on Indian investors investing in Nevro Corp. Get details on the Indian mutual funds that are investing in Nevro Corp. Get Analyst recommendations and forecasts along with all the Nevro Corp's financials.

Nevro Corp share price movements

$4.13
$4.44
$4.35
5.06%
Downside
Day's Volatility :6.98%
Upside
2.03%
$3.95
$22.64
$4.35
9.2%
Downside
52 Weeks Volatility :82.55%
Upside
80.79%

Nevro Corp Returns

Period	Nevro Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	-15.91%	-6.4%	0.0%
6 Months	-56.09%	-0.9%	0.0%
1 Year	-79.71%	9.9%	0.0%
3 Years	-95.19%	8.2%	-20.3%

Nevro Corp Key Statistics

in dollars & INR

Previous Close	$4.19
Open	$4.17
Today's High	$4.44
Today's Low	$4.13
Market Capitalization	$155.1M
Today's Volume	$546.7K
52 Week High	$22.64
52 Week Low	$3.95
Revenue TTM	$419.1M
EBITDA	$-73.2M
Earnings Per Share (EPS)	$-1.82
Profit Margin	-16.54%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-24.78%

How to invest in Nevro Corp from India?

It is very easy for Indian residents to invest directly in Nevro Corp from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Nevro Corp stock in both rupees (INR) and dollars (USD). Search for Nevro Corp or NVRO on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Nevro Corp or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Nevro Corp shares which would translate to 0.195 fractional shares of Nevro Corp as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Nevro Corp

-14%

Period: Sep 10, 2024 to Dec 9, 2024. Change in 30 Days versus previous period

Search volume for Nevro Corp on INDmoney from India has reduced in the last 30 days as on Dec 10, 2024. -14% less investors are searching Nevro Corp in the last 30 days versus the previous period.

Global Institutional Holdings in Nevro Corp

ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
11.72%
Armistice Capital, LLC
9.95%
BlackRock Inc
9.61%
Engaged Capital LLC
6.52%
Vanguard Group Inc
5.59%
BRAIDWELL LP
4.53%

Analyst Recommendation on Nevro Corp

Hold

4%Buy

65%Hold

30%Sell

Based on 23 Wall street analysts offering stock ratings for Nevro Corp(by analysts ranked 0 to 5 stars)

Based on 23 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Nevro Corp

What analysts predicted

Upside of 48.47%

Current:

$4.35

Target:

$6.46

Insights on Nevro Corp

Price Movement
In the last 1 month, NVRO stock has moved down by -19.9%
Decreasing Revenue
Revenue is down for the last 2 quarters, 104.16M → 96.91M (in $), with an average decrease of 7.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -25.40M → -15.34M (in $), with an average increase of 28.7% per quarter
NVRO vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 64.7% return, outperforming this stock by 144.3%
NVRO vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 119.3% return, outperforming this stock by 214.8%
Price to Sales
ForNVRO every $1 of sales, investors are willing to pay $0.4, whereas for Boston Scientific Corp., the investors are paying $8.3 for every $1 of sales.

Nevro Corp Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$387.3M	↑ 18.56%
Net Income	$-49.2M	↑ 34.23%
Net Profit Margin	-12.7%	↓ 1.48%

	FY19	Y/Y Change
Revenue	$390.3M	↑ 0.77%
Net Income	$-103.7M	↑ 110.72%
Net Profit Margin	-26.57%	↓ 13.87%

	FY20	Y/Y Change
Revenue	$362.0M	↓ 7.23%
Net Income	$-83.1M	↓ 19.89%
Net Profit Margin	-22.94%	↑ 3.63%

	FY21	Y/Y Change
Revenue	$386.9M	↑ 6.87%
Net Income	$-131.4M	↑ 58.14%
Net Profit Margin	-33.95%	↓ 11.01%

	FY22	Y/Y Change
Revenue	$406.4M	↑ 5.03%
Net Income	$3.0M	↓ 102.28%
Net Profit Margin	0.74%	↑ 34.69%

	FY23	Y/Y Change
Revenue	$425.2M	↑ 4.63%
Net Income	$-92.2M	↓ 3172.74%
Net Profit Margin	-21.69%	↓ 22.43%

	Q2 FY23	Q/Q Change
Revenue	$108.8M	↑ 12.96%
Net Income	$-24.7M	↓ 29.42%
Net Profit Margin	-22.72%	↑ 13.64%

	Q3 FY23	Q/Q Change
Revenue	$103.9M	↓ 4.55%
Net Income	$-23.5M	↓ 5.04%
Net Profit Margin	-22.61%	↑ 0.11%

	Q4 FY23	Q/Q Change
Revenue	$116.2M	↑ 11.86%
Net Income	$-9.0M	↓ 61.75%
Net Profit Margin	-7.73%	↑ 14.88%

	Q1 FY24	Q/Q Change
Revenue	$101.9M	↓ 12.29%
Net Income	$-25.4M	↑ 182.92%
Net Profit Margin	-24.94%	↓ 17.21%

	Q2 FY24	Q/Q Change
Revenue	$104.2M	↑ 2.22%
Net Income	$-19.6M	↓ 22.96%
Net Profit Margin	-18.79%	↑ 6.15%

	Q3 FY24	Q/Q Change
Revenue	$96.9M	↓ 6.96%
Net Income	$-15.3M	↓ 21.61%
Net Profit Margin	-15.83%	↑ 2.96%

	FY18	Y/Y Change
Total Assets	$463.1M	↑ 2.0%
Total Liabilities	$217.6M	↑ 6.22%

	FY19	Y/Y Change
Total Assets	$469.6M	↑ 1.41%
Total Liabilities	$253.3M	↑ 16.39%

	FY20	Y/Y Change
Total Assets	$789.4M	↑ 68.09%
Total Liabilities	$401.0M	↑ 58.3%

	FY21	Y/Y Change
Total Assets	$574.5M	↓ 27.22%
Total Liabilities	$270.9M	↓ 32.43%

	FY22	Y/Y Change
Total Assets	$602.4M	↑ 4.85%
Total Liabilities	$278.5M	↑ 2.81%

	FY23	Y/Y Change
Total Assets	$635.7M	↑ 5.53%
Total Liabilities	$342.6M	↑ 22.99%

	Q2 FY23	Q/Q Change
Total Assets	$569.5M	↓ 0.85%
Total Liabilities	$274.8M	↑ 0.58%

	Q3 FY23	Q/Q Change
Total Assets	$561.6M	↓ 1.39%
Total Liabilities	$275.9M	↑ 0.42%

	Q4 FY23	Q/Q Change
Total Assets	$635.7M	↑ 13.2%
Total Liabilities	$330.3M	↑ 19.71%

	Q1 FY24	Q/Q Change
Total Assets	$596.1M	↓ 6.24%
Total Liabilities	$317.5M	↓ 3.88%

	Q2 FY24	Q/Q Change
Total Assets	$603.3M	↑ 1.22%
Total Liabilities	$329.1M	↑ 3.64%

	Q3 FY24	Q/Q Change
Total Assets	$595.6M	↓ 1.27%
Total Liabilities	$322.0M	↓ 2.15%

	FY18	Y/Y Change
Operating Cash Flow	$-5.7M	↓ 60.01%
Investing Cash Flow	$6.4M	↑ 58.1%
Financing Cash Flow	$7.8M	↓ 30.76%

	FY19	Y/Y Change
Operating Cash Flow	$-50.2M	↑ 779.91%
Investing Cash Flow	$32.3M	↑ 402.56%
Financing Cash Flow	$32.1M	↑ 313.89%

	FY20	Y/Y Change
Operating Cash Flow	$1.2M	↓ 102.37%
Investing Cash Flow	$-369.9M	↓ 1244.04%
Financing Cash Flow	$346.9M	↑ 980.94%

	FY21	Y/Y Change
Operating Cash Flow	$-41.9M	↓ 3616.46%
Investing Cash Flow	$201.7M	↓ 154.54%
Financing Cash Flow	$-169.4M	↓ 148.83%

	FY22	Y/Y Change
Operating Cash Flow	$24.7M	↓ 158.92%
Investing Cash Flow	$64.3M	↓ 68.13%
Financing Cash Flow	$-2.5M	↓ 98.55%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-14.5M	↓ 50.53%
Investing Cash Flow	$11.3M	↓ 145.74%
Financing Cash Flow	$4.1M	↓ 281.35%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-6.1M	↓ 58.01%
Investing Cash Flow	$7.3M	↓ 35.4%
Financing Cash Flow	$-1.0M	↓ 124.58%

Nevro Corp Technicals Summary

Sell

Neutral

Buy

Nevro Corp is currently in a neutral trading position according to technical analysis indicators.

Nevro Corp Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Nevro Corp	-23.5%	-56.09%	-79.71%	-95.19%	-96.22%
Stryker Corporation	0.95%	10.41%	30.52%	47.06%	91.45%
Boston Scientific Corp.	2.32%	17.34%	63.83%	118.51%	102.66%
Edwards Lifesciences Corp.	8.59%	-16.75%	3.02%	-40.01%	-5.81%
Abbott Laboratories	-1.04%	9.24%	8.82%	-14.98%	34.45%
Medtronic Plc	-4.68%	2.67%	5.54%	-25.45%	-25.13%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Nevro Corp	157.5	NA	-3.13	-2.35	-0.25	-0.09	NA	7.31
Stryker Corporation	40.99	40.99	2.67	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	74.82	74.82	1.64	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	28.63	28.63	6.78	2.52	0.19	0.11	NA	16.18
Abbott Laboratories	35.24	35.24	2.25	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	26.38	26.38	1.56	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Nevro Corp	Hold	$155.1M	-96.22%	157.5	-16.54%
Stryker Corporation	Buy	$145.8B	91.45%	40.99	16.34%
Boston Scientific Corp.	Buy	$133.9B	102.66%	74.82	11.26%
Edwards Lifesciences Corp.	Buy	$42.7B	-5.81%	28.63	65.86%
Abbott Laboratories	Buy	$201.1B	34.45%	35.24	13.99%
Medtronic Plc	Buy	$110.6B	-25.13%	26.38	12.06%

About Nevro Corp

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.

Organization	Nevro Corp
Employees	1215
CEO	Mr. Kevin R. Thornal
Industry	Health Technology

Management People of Nevro Corp

Name	Title
Mr. Kevin R. Thornal	President, CEO & Director
Mr. Roderick H. MacLeod	Senior VP & CFO
Mr. Kashif Rashid J.D.	Senior VP of Corporate Development & Chief Legal Officer
Mr. Greg Siller	Senior VP & Chief Commercial Officer
Mr. Christofer Christoforou	Senior VP & COO
Ms. Angeline C. McCabe	Vice President of Investor Relations & Corporate Communications
Ms. Shana D. Ross M.B.A.	Senior VP & Chief Human Resources Officer
Dr. David Caraway M.D., Ph.D.	Senior VP & Chief Medical Officer
Mr. Peter A. Socarras	VP, General Counsel & Corporate Secretary

Important FAQs about investing in Nevro Corp from India :

What is Nevro Corp share price today?

Nevro Corp (NVRO) share price today is $4.35.

Can Indians buy Nevro Corp shares?

Yes, Indians can invest in the Nevro Corp (NVRO) from India.

With INDmoney, you can buy Nevro Corp at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Nevro Corp at zero transaction cost.

How can I buy Nevro Corp shares from India?

It is very easy to buy Nevro Corp from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Nevro Corp be purchased?

Yes, you can buy fractional shares of Nevro Corp with INDmoney app.

What are the documents required to start investing in Nevro Corp stocks?

To start investing in Nevro Corp, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Nevro Corp

Today’s highest price of Nevro Corp (NVRO) is $4.44.

Today’s lowest price of Nevro Corp (NVRO) is $4.13.

What is today's market capitalisation of Nevro Corp

Today's market capitalisation of Nevro Corp NVRO is 155.1M

What is the 52 Week High and Low Range of Nevro Corp

52 Week High
$22.64
52 Week Low
$3.95

How much percentage Nevro Corp is down from its 52 Week High?

Nevro Corp (NVRO) share price is $4.35. It is down by 80.79% from its 52 Week High price of $22.64.

How much percentage Nevro Corp is up from its 52 Week low?

Nevro Corp (NVRO) share price is $4.35. It is up by 10.13% from its 52 Week Low price of $3.95.

What are the historical returns of Nevro Corp?

1 Month Returns
-23.5%
3 Months Returns
-56.09%
1 Year Returns
-79.71%
5 Years Returns
-96.22%

Who is the Chief Executive Officer (CEO) of Nevro Corp

Mr. Kevin R. Thornal is the current Chief Executive Officer (CEO) of Nevro Corp.

Discover More

Explore all